The consensus EPS Estimate is $1.68 (vs $0.03 in Q4 2023) and the consensus Revenue Estimate is $15.51B (+6.2% Y/Y). Over the last 2 years, MRK has beaten EPS estimates 88% of the time and has ...

Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsFlorian Schraeder - Head of Investor ...

Merck reported $64.2 billion in sales for 2024, a 7% increase compared with 2023. That is near Wall Street's consensus of $64 billion. Earnings per share came in at $7.65, just above Wall Street's ...

Merck KGaA (MKGAF) reports robust Q4 results with significant growth across sectors, despite challenges in Life Science and ...

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.

RAHWAY, N.J. (AP) — RAHWAY, N.J. (AP) — Merck & Co. (MRK) on Tuesday reported fourth-quarter net income of $3.74 billion. On a per-share basis, the Rahway, New Jersey-based company said it had ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

Merck & Company Inc. (MRK) reported its financial results for the full year 2024, showing a slight increase in net sales and a notable improvement in operating cash flow. The company’s stock ...

Merck unveils a $1 billion vaccine manufacturing facility in Durham, North Carolina, expanding its U.S. production and ...

Merck & Company Inc. (MRK) reported its financial results for the full year 2024, showing a slight increase in net sales and a notable improvement in operating cash flow. The company’s stock ...